查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球生技藥品CDMO 市場：2023-2033
市場調查報告書
商品編碼
1379213

全球生技藥品CDMO 市場：2023-2033

Global Biologics CDMO Market - A Global and Regional Analysis, 2023-2033
出版日期: | 出版商: BIS Research | 英文 165 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

全球生技藥品CDMO 市場預計將在創新和需求浪潮中快速成長。

全球生技藥品CDMO 市場透過為生技藥品的開發、製造和測試提供專業服務，在製藥和生物技術產業中發揮重要作用。生技藥品是源自活生物體的複雜分子，例如蛋白質、抗體和核酸，在治療多種疾病（包括癌症、自體免疫疾病和感染疾病）方面變得越來越重要。

本報告調查了全球生技藥品CDMO 市場，並提供了市場概況，分析了市場成長的各種影響因素、法律制度、市場規模趨勢和預測，並對各個細分市場、地區和主要國家進行了詳細分析、競爭形勢、主要企業分析等

市場區隔：

細分 1：按細胞類型

  • 哺乳動物的
  • 非哺乳動物

細分 2：依產品類型

  • 生技藥品
    • 單株抗體
    • 重組蛋白
    • 反義/分子藥物
    • 疫苗
    • 其他
  • 生物相似藥

細分 3：按地區

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

目錄

第1章 市場：產業展望

  • 趨勢：當前和未來的影響評估
    • 新的基因療法和細胞療法
    • 免洗生物加工設備
    • 個人化醫療的趨勢
  • 供應鏈概覽
    • 價值鏈分析
    • 市場地圖
    • 製造成本預測：CDMO/gm
  • 專利分析
  • 法規狀況
  • 製造能力
  • 外包給 CDMO 時考慮的因素
  • 世界重大事件的影響分析：COVID-19、俄羅斯/烏克蘭、中東危機
  • 市場動態概覽
    • 市場促進因素
    • 市場抑制因素
    • 市場機會

第2章 應用

  • 使用分類
  • 應用概述
  • 全球生技藥品CDMO 市場（按細胞類型）
    • 哺乳動物的
    • 非哺乳動物

第3章 產品

  • 產品分類
  • 產品概要
  • 全球生技藥品CDMO 市場（依產品類型）
    • 生技藥品
    • 生物相似藥

第4章 區域

  • 區域概況
  • 促進因素/抑制因素
  • 北美洲
    • 主要參與企業
    • 業務促進因素
    • 業務挑戰
    • 目的
    • 產品
    • 北美洲（按國家/地區）
  • 歐洲
    • 主要參與企業
    • 業務促進因素
    • 業務挑戰
    • 目的
    • 產品
    • 歐洲（按國家/地區）
  • 亞太地區
    • 主要參與企業
    • 業務促進因素
    • 業務挑戰
    • 目的
    • 產品
    • 亞太地區（按國家/地區）
  • 拉丁美洲
    • 主要參與企業
    • 業務促進因素
    • 業務挑戰
    • 目的
    • 產品
    • 拉丁美洲（按國家/地區）
  • 中東/非洲
    • 主要參與企業
    • 業務促進因素
    • 業務挑戰
    • 目的
    • 產品
    • 中東/非洲（按國家）

第5章 市場：競爭形勢/公司簡介

  • 競爭形勢
  • 公司簡介
    • Boehringer Ingelheim Group
    • Lonza Group
    • Samsung Biologics
    • NOVARTIS AG
    • Toyobo Co. Limited
    • Parexel International Corporation
    • Catalent Inc.
    • Binex Co. Limited
    • AGC Biologics
    • AbbVie Contract Manufacturing
簡介目錄
Product Code: BHL1501SA

“Global Biologics CDMO Market Set to Surge, Riding the Wave of Innovation and Demand.”

Biologics CDMO Industry Overview

Introduction to Biologics CDMO Market

The global biologics CDMO market plays a crucial role in the pharmaceutical and biotechnology industries, offering specialized services for the development, manufacturing, and testing of biologic drugs. Biologics are complex molecules derived from living organisms, such as proteins, antibodies, and nucleic acids, and they have become increasingly important in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases.

CDMOs in the biologics sector provide a range of services, including cell line development, process development, scale-up, manufacturing, quality control, and regulatory support. These organizations serve as strategic partners for pharmaceutical and biotech companies, allowing them to outsource certain aspects of the drug development and manufacturing process, thereby gaining efficiency, expertise, and flexibility.

Market Segmentation:

Segmentation 1: by Cell Type

  • Mammalian
  • Non-mammalian

Segmentation 2: by Product Type

  • Biologics
    • Monoclonal Antibodies
    • Recombinant Proteins
    • Antisense and Molecular Therapy
    • Vaccines
    • Other Biologics
  • Biosimilars

Segmentation 3: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • MEA

The report provides data for each of these regions, with in-depth country-level analyses, all covering the period from 2022 to 2033.

SegmentationHow can this report add value to an organization?

Product/Innovation Strategy: The global biologics CDMO market has been extensively segmented based on various categories, such as cell type and product type. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: The global biologics CDMO market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint venture.

Competitive Strategy: Key players in the global biologics CDMO market analyzed and profiled in the study involve established and emerging players. Moreover, a detailed competitive benchmarking of the players operating in the global biologics CDMO market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

SegmentationSome of the prominent names established in this market are:

  • Boehringer Ingelheim Group
  • Lonza Group
  • Samsung Biologics
  • NOVARTIS AG
  • Toyobo Co. Limited
  • Parexel International Corporation
  • Catalent Inc.
  • Binex Co. Limited
  • AGC Biologics
  • AbbVie Contract Manufacturing

Table of Contents

1. Markets: Industry Outlook

  • 1.1. Trends: Current and Future Impact Assessment
    • 1.1.1. Emerging Gene and Cell Therapies
    • 1.1.2. Single-use Bioprocessing Equipment
    • 1.1.3. Trend Toward Personalized Medicine
  • 1.2. Supply Chain Overview
    • 1.2.1. Value chain Analysis
    • 1.2.2. Market Map
    • 1.2.3. Cost of Manufacturing in CDMO/gm Forecast
  • 1.3. Patent Analysis
    • 1.3.1. Awaited Technological Developments
    • 1.3.2. Patent Filing Trend by Country, by Year
    • 1.3.3. Patent Filing Trend by Country, by Country
  • 1.4. Regulatory Landscape
  • 1.5. Prodution Capacity
  • 1.6. Factors Considered While Outsourcing To CDMO
  • 1.7. Impact analysis for key global events- covid19, Russia/Ukraine or Middle East crisis
  • 1.8. Market Dynamics Overview
    • 1.8.1. Market Drivers
    • 1.8.2. Market Restraints
    • 1.8.3. Market Opportunities

2. Application

  • 2.1. Application Segmentation
  • 2.2. Application Summary
  • 2.3. Global Biologiv CDMO Market (by Cell Type)
    • 2.3.1. Mammalian
    • 2.3.2. Non-mammalian

3. Product

  • 3.1. Product Segmentation
  • 3.2. Product Summary
  • 3.3. Global Biologics CDMO Market (by Product Type)
    • 3.3.1. Biologics
      • 3.3.1.1. Monoclonal Antibodies
      • 3.3.1.2. Recombinant Proteins
      • 3.3.1.3. Antisense and Molecular Therapy
      • 3.3.1.4. Vaccines
      • 3.3.1.5. Other Biologics
    • 3.3.2. Biosimilars

4. Region

  • 4.1. Regional Summary
    • Table: Biologics CDMO Market, By Region, ($ Million), 2022-2033
  • 4.2. Drivers and Restraints
  • 4.3. North America
    • Key Market Participants in North America
    • Business Drivers
    • Business Challenges
    • 4.3.1. Application
      • Table: North America Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.3.2. Product
      • Table: North America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.3.3. North America (by Country)
      • 4.3.3.1. U.S.
        • Table: U.S. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: U.S. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.3.3.2. Canada
        • Table: U.S. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: U.S. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
  • 4.4. Europe
    • Key Market Participants in Europe
    • Business Drivers
    • Business Challenges
    • 4.4.1. Application
      • Table: Europe Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.4.2. Product
      • Table: Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.4.3. Europe (by Country)
      • 4.4.3.1. U.K.
        • Table: U.K.Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: U.K. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.2. Germany
        • Table: Germany Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Germany Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.3. Italy
        • Table: Italy Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Italy Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.4. France
        • Table: France Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: France Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.5. Spain
        • Table: Spain Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Spain Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.6. Rest of Europe
        • Table: Rest of Europe Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Rest of Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
  • 4.5. Asia Pacific
    • Key Market Participants in Asia Pacific
    • Business Drivers
    • Business Challenges
    • 4.5.1. Application
      • Table: Europe Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.5.2. Product
      • Table: Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.5.3. Asia Pacific (by Country)
      • 4.5.3.1. China
        • Table: China Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: China Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.5.3.2. Japan
        • Table: Japan Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Japan Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.5.3.3. India
        • Table: India Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: India Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.5.3.4. Australia
        • Table: Australia Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Australia Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.5.3.5. Rest of APAC
        • Table: Rest of APAC Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Rest of APAC Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
  • 4.6. Latin America
    • Key Market Participants in Latin America
    • Business Drivers
    • Business Challenges
    • 4.6.1. Application
      • Table: Latin America Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.6.2. Product
      • Table: Latin America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.6.3. Latin America (by Country)
      • 4.6.3.1. Brazil
        • Table: Brazil Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Brazil Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.6.3.2. Mexico
        • Table: Mexico Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Mexico Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.6.3.3. Rest of Latin America
        • Table: Rest of Latin America Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Rest of Latin America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
  • 4.7. MEA
    • Key Market Participants in MEA
    • Business Drivers
    • Business Challenges
    • 4.7.1. Application
      • Table: MEA Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.7.2. Product
      • Table: MEA Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.7.3. MEA (by Country)
      • 4.7.3.1. Saudi Arabia
        • Table: Saudi Arabia Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Saudi Arabia Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.7.3.2. U.A.E.
        • Table: U.A.E. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: U.A.E. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.7.3.3. Rest of MEA
        • Table: Rest of MEA Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Rest of MEA Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033

5. Markets - Competitive Landscape & Company Profiles

  • 5.1. Competitive Landscape
  • 5.2. Company Profile
    • 5.2.1. Boehringer Ingelheim Group
      • 5.2.1.1. Company Overview
        • 5.2.1.1.1. Role of Boehringer Ingelheim Group in Biologics CDMO Market
        • 5.2.1.1.2. Product Portfolio
      • 5.2.1.2. Business Strategies
      • 5.2.1.3. Corporate Strategies
      • 5.2.1.4. Analyst View
    • 5.2.2. Lonza Group
      • 5.2.2.1. Company Overview
        • 5.2.2.1.1. Role of Lonza Group in Biologics CDMO Market
        • 5.2.2.1.2. Product Portfolio
      • 5.2.2.2. Business Strategies
      • 5.2.2.3. Corporate Strategies
      • 5.2.2.4. Analyst View
    • 5.2.3. Samsung Biologics
      • 5.2.3.1. Company Overview
        • 5.2.3.1.1. Role of Samsung Biologics in Biologics CDMO Market
        • 5.2.3.1.2. Product Portfolio
      • 5.2.3.2. Business Strategies
      • 5.2.3.3. Corporate Strategies
      • 5.2.3.4. Analyst View
    • 5.2.4. NOVARTIS AG
      • 5.2.4.1. Company Overview
        • 5.2.4.1.1. Role of NOVARTIS AG in Biologics CDMO Market
        • 5.2.4.1.2. Product Portfolio
      • 5.2.4.2. Business Strategies
      • 5.2.4.3. Corporate Strategies
      • 5.2.4.4. Analyst View
    • 5.2.5. Toyobo Co. Limited
      • 5.2.5.1. Company Overview
        • 5.2.5.1.1. Role of Toyobo Co. Limited Group in Biologics CDMO Market
        • 5.2.5.1.2. Product Portfolio
      • 5.2.5.2. Business Strategies
      • 5.2.5.3. Corporate Strategies
      • 5.2.5.4. Analyst View
    • 5.2.6. Parexel International Corporation
      • 5.2.6.1. Company Overview
        • 5.2.6.1.1. Role of Parexel International Corporation in Biologics CDMO Market
        • 5.2.6.1.2. Product Portfolio
      • 5.2.6.2. Business Strategies
      • 5.2.6.3. Corporate Strategies
      • 5.2.6.4. Analyst View
    • 5.2.7. Catalent Inc.
      • 5.2.7.1. Company Overview
        • 5.2.7.1.1. Role of Catalent Inc. in Biologics CDMO Market
        • 5.2.7.1.2. Product Portfolio
      • 5.2.7.2. Business Strategies
      • 5.2.7.3. Corporate Strategies
      • 5.2.7.4. Analyst View
    • 5.2.8. Binex Co. Limited
      • 5.2.8.1. Company Overview
        • 5.2.8.1.1. Role of Binex Co. Limited in Biologics CDMO Market
        • 5.2.8.1.2. Product Portfolio
      • 5.2.8.2. Business Strategies
      • 5.2.8.3. Corporate Strategies
      • 5.2.8.4. Analyst View
    • 5.2.9. AGC Biologics
      • 5.2.9.1. Company Overview
        • 5.2.5.1.1. Role of AGC Biologics in Biologics CDMO Market
        • 5.2.5.1.2. Product Portfolio
      • 5.2.9.2. Business Strategies
      • 5.2.9.3. Corporate Strategies
      • 5.2.9.4. Analyst View
    • 5.2.10. AbbVie Contract Manufacturing
      • 5.2.10.1. Company Overview
        • 5.2.10.1.1. Role of AbbVie Contract Manufacturing in Biologics CDMO Market
        • 5.2.10.1.2. Product Portfolio
      • 5.2.10.2. Business Strategies
      • 5.2.10.3. Corporate Strategies
      • 5.2.10.4. Analyst View